Rhenman & Partners Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.6M	Buy	24,050 +4,500	+23%	+$2.15M	1.55%	21
2025 Q4	$11.4M	Buy	19,550 +1,300	+7%	+$664K	1.06%	37
2025 Q3	$8.37M	Buy	+18,250	New	+$6.81M	0.93%	40
2024 Q4	–	Sell	-15,300	Closed	-$3.25M	–	97
2024 Q3	$3.25M	Sell	15,300 -11,200	-42%	-$2.87M	0.26%	79
2024 Q2	$7.42M	Sell	26,500 -10,000	-27%	-$2.38M	0.71%	41
2024 Q1	$9.75M	Buy	36,500 +14,000	+62%	+$3.3M	0.92%	39
2023 Q4	$5.21M	Buy	+22,500	New	+$3.94M	0.52%	59
2019 Q4	–	Sell	-30,000	Closed	-$2.59M	–	98
2019 Q3	$2.59M	Sell	30,000 -7,225	-19%	-$678K	0.32%	71
2019 Q2	$3.9M	Buy	37,225 +10,000	+37%	+$1.07M	0.43%	62
2019 Q1	$3.41M	Buy	+27,225	New	+$3.38M	0.4%	64
2014 Q1	–	Sell	-2,857	Closed	-$524K	–	97
2013 Q4	$524K	Buy	+2,857	New	+$523K	0.21%	81